Literature DB >> 18981727

MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway.

Deepak Raina1, Rehan Ahmad, Dongshu Chen, Shailendra Kumar, Surender Kharbanda, Donald Kufe.   

Abstract

The MUC1 oncoprotein interacts with the c-Abl tyrosine kinase and blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. Mutation of the MUC1 cytoplasmic domain at Tyr-60 disrupts the MUC1-c-Abl interaction. The present results demonstrate that the MUC1(Y60F) mutant is a potent inducer of the ARF tumor suppressor. MUC1(Y60F) induces transcription of the ARF locus by a c-Abl-dependent mechanism that promotes CUL-4A-mediated nuclear export of the replication protein Cdc6. The functional significance of these findings is that MUC1(Y60F)-induced ARF expression and thereby inhibition of MDM2 results in the upregulation of p53 and the homeodomain interacting protein kinase 2 (HIPK2) serine/threonine kinase. HIPK2-mediated phosphorylation of p53 on Ser-46 was further associated with a shift from expression of the cell cycle arrest-related p21 gene to the apoptosis-related PUMA gene. We also show that the MUC1(Y60F) mutant functions as dominant negative inhibitor of tumorigenicity. These findings indicate that the oncogenic function of MUC1 is conferred by suppressing activation of the ARF-MDM2-p53 pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981727      PMCID: PMC3023907          DOI: 10.4161/cbt.7.12.6956

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  54 in total

1.  Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion.

Authors:  M Yamamoto; A Bharti; Y Li; D Kufe
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

2.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

3.  Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response.

Authors:  Xiaolong Wei; Hai Xu; Donald Kufe
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

Review 4.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

5.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

6.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

7.  Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas.

Authors:  G R Merlo; J Siddiqui; C S Cropp; D S Liscia; R Lidereau; R Callahan; D W Kufe
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

8.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

9.  A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats.

Authors:  S Gendler; J Taylor-Papadimitriou; T Duhig; J Rothbard; J Burchell
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

10.  Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin.

Authors:  Y Li; A Bharti; D Chen; J Gong; D Kufe
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more
  11 in total

1.  Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.

Authors:  Qiang Fu; Guoqiang Zhang; Hongwei Chen; Youwei Zheng; Jing Cheng
Journal:  Tumour Biol       Date:  2013-08-03

2.  Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

Authors:  Robin R Hodges; Darlene A Dartt
Journal:  Exp Eye Res       Date:  2013-08-14       Impact factor: 3.467

3.  The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.

Authors:  Nina Reuven; Julia Adler; Ziv Porat; Tilman Polonio-Vallon; Thomas G Hofmann; Yosef Shaul
Journal:  J Biol Chem       Date:  2015-05-05       Impact factor: 5.157

4.  Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Authors:  Neeley Remmers; Judy M Anderson; Erin M Linde; Dominick J DiMaio; Audrey J Lazenby; Hans H Wandall; Ulla Mandel; Henrik Clausen; Fang Yu; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

Review 5.  Functional targeting of the MUC1 oncogene in human cancers.

Authors:  Donald W Kufe
Journal:  Cancer Biol Ther       Date:  2009-07-27       Impact factor: 4.742

6.  MUC1 drives c-Met-dependent migration and scattering.

Authors:  Teresa M Horm; Benjamin G Bitler; Derrick M Broka; Jeanne M Louderbough; Joyce A Schroeder
Journal:  Mol Cancer Res       Date:  2012-11-27       Impact factor: 5.852

7.  The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF.

Authors:  M E Behrens; P M Grandgenett; J M Bailey; P K Singh; C-H Yi; F Yu; M A Hollingsworth
Journal:  Oncogene       Date:  2010-08-09       Impact factor: 9.867

8.  MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis.

Authors:  Q Zhao; T Piyush; C Chen; M A Hollingsworth; J Hilkens; J M Rhodes; L-G Yu
Journal:  Cell Death Dis       Date:  2014-10-02       Impact factor: 8.469

9.  MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner.

Authors:  Wei Jin; Xiaodong Liao; Yaping Lv; Zhi Pang; Yuming Wang; Quanfu Li; Yahui Liao; Qing Ye; Guoqiang Chen; Kewen Zhao; Lei Huang
Journal:  Cell Death Dis       Date:  2017-08-10       Impact factor: 8.469

Review 10.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Authors:  Mildred Felder; Arvinder Kapur; Jesus Gonzalez-Bosquet; Sachi Horibata; Joseph Heintz; Ralph Albrecht; Lucas Fass; Justanjyot Kaur; Kevin Hu; Hadi Shojaei; Rebecca J Whelan; Manish S Patankar
Journal:  Mol Cancer       Date:  2014-05-29       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.